 ASAQ was handed over to the MMV Access and Product Management Team in May 2015.The second antimalarial treatment developed by DND"i" is a fixed-dose combination of artesunate and mefloquine launched in 2008.It was developed by an international collaboration within the FACT Project Consortium.